Investment
Features
FeesSafety
Academy
More
Pluang+

Delta Resources to present Delta-1 Gold Project at 2026 Precious Metals Summit in Colorado

Market News
18 Sep 2026
Newsfile Corp
View Source
Bullish
Delta Resources to present Delta-1 Gold Project at 2026 Precious Metals Summit in Colorado

Delta Resources Limited will attend the 2026 Precious Metals Summit in Beaver Creek, Colorado, showcasing its Delta-1 Gold Project near Thunder Bay, Ontario. The project features the Eureka Gold Deposit with promising drill results and benefits from strong infrastructure access. Delta's management will update investors on ongoing exploration and plans to start drilling soon in key areas. This event offers Delta a platform to engage institutional investors and highlight its district-scale gold exploration potential.

Delta Resources attending the 2026 Precious Metals Summit provides context for readers interested in precious metals. For readers following Basic Materials-sector US stocks on Pluang, here is the market snapshot as of Sep 18, 2026 17:42 WIB: out of 33 priced stocks, 24 rose and 9 fell. Barrick Gold Corp (B) was priced at USD 44.25 with a 1-day change of +1.29% and Pluang order activity of 87% Sell / 13% Buy. Newmont Corporation (NEM) was priced at USD 125.91 with a 1-day change of +1.22% and Pluang order activity of 30% Sell / 70% Buy.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
24 minutes ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
1 hour ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
1 hour ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
2 hours ago
Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...

Analyst Insights
Bearish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App